Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Université de Montréal

$82,500.00

Assessing the therapeutic potential of E4F1, a new protein of the DNA damage response, in cancer treatment.

FY 2015-16

Summary
The lifetime conservation of tissue integrity relies upon a delicate balance between cell division and differentiation. This requires a reliable system to protect the genetic information against harmful DNA damages. Thus, to prevent genetic instability and ensure cell integrity, cells have elaborated sophisticated mechanisms to detect and repair DNA lesions. Cancer cells share common features, including uncontrolled proliferation. These highly dividing cells are more susceptible to accumulate DNA lesions and need an efficient DNA repair system to survive. This feature has been exploited for many years in cancer therapy, where the combination of chemotherapy and radiotherapy is designed to induce massive DNA lesions and ultimately cell death. In order to improve the efficiency of these therapies, it has been proposed to target key players of the DNA damage response. The checkpoint protein CHK1 controls cell cycle progression together with DNA repair and therefore represents a promising target for cancer treatment. By inhibiting CHK1, cancer cells carrying DNA lesions induced by classical chemotherapies won't be able to sufficiently preserve their genomic integrity and will be more likely to die. In this context, we propose to study the E4F1 protein. Indeed, we recently identified E4F1 as a master regulator of CHK1 stability and activity. We showed that E4F1 maintains genome integrity and is directly involved in the DNA damage pathways. Our proposed research is aimed at (1) uncovering the precise role of E4F1 in the DNA damage response, (2) identifying new E4F1 partners in order to better understand its cellular functions, and (3) assessing its therapeutic potential by monitoring the impact of E4f1 deletion in human tumor samples. This project combines fundamental research to uncover the cellular functions of E4F1 and aim to translate this knowledge into clinical applications by assessing its therapeutic potential for cancer treatment.
Program
CIHR Fellowship
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
339507
Name
Moison Céline
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Assessing the therapeutic potential of E4F1, a new protein of the DNA damage response, in cancer treatment.
Programtype2
Fellowship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$82,500
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer Therapy; Chk1; Confocal Microscopy; Dna Damage Pathway; E4f1; Leukemia; Primary Tumor Samples; Proteomics
Abstract
The lifetime conservation of tissue integrity relies upon a delicate balance between cell division and differentiation. This requires a reliable system to protect the genetic information against harmful DNA damages. Thus, to prevent genetic instability and ensure cell integrity, cells have elaborated sophisticated mechanisms to detect and repair DNA lesions. Cancer cells share common features, including uncontrolled proliferation. These highly dividing cells are more susceptible to accumulate DNA lesions and need an efficient DNA repair system to survive. This feature has been exploited for many years in cancer therapy, where the combination of chemotherapy and radiotherapy is designed to induce massive DNA lesions and ultimately cell death. In order to improve the efficiency of these therapies, it has been proposed to target key players of the DNA damage response. The checkpoint protein CHK1 controls cell cycle progression together with DNA repair and therefore represents a promising target for cancer treatment. By inhibiting CHK1, cancer cells carrying DNA lesions induced by classical chemotherapies won't be able to sufficiently preserve their genomic integrity and will be more likely to die. In this context, we propose to study the E4F1 protein. Indeed, we recently identified E4F1 as a master regulator of CHK1 stability and activity. We showed that E4F1 maintains genome integrity and is directly involved in the DNA damage pathways. Our proposed research is aimed at (1) uncovering the precise role of E4F1 in the DNA damage response, (2) identifying new E4F1 partners in order to better understand its cellular functions, and (3) assessing its therapeutic potential by monitoring the impact of E4f1 deletion in human tumor samples. This project combines fundamental research to uncover the cellular functions of E4F1 and aim to translate this knowledge into clinical applications by assessing its therapeutic potential for cancer treatment.
Competitiondate
201511
Approvedterm2
1 yr 10 mths
Pinamesdelim
Moison, Céline
Approvedterm
1 an 10 mois
Cihrcontribution2
~ $82,500~ $0~
Université de Montréal - $82,500 Grant (2015-16) | Canada Spends